Gilead Sciences and Pharmstandard made the announcement on the conclusion of the agreement. According to the agreement Pharmstandard production facilities will manufacture Sovaldi® (sofosbuvir) for the treatment of chronic hepatitis C and Truvada® (emtricitabine / tenofovir disoproxil fumarate) for the treatment of HIV.
Igor Rukavishnikov, General Manager, Gilead Russia, stated:
“Hepatitis C and HIV are significant public health problems in many countries, including Russia. We are confident that our partnership will facilitate access to innovative methods of treatment of these diseases developed by Gilead for many people in Russia and will enable them to live longer and healthier lives.”
Grigory Potapov, General Director of JSC “Pharmstandard”, commented:
“We are proud of our partnership with Gilead, the world leader in the production of innovative drugs for the treatment of HIV infection and chronic viral hepatitis. For both companies, this is a very important step, which confirms the seriousness of our intentions in increasing the availability of drug therapy for Russian patients. The first drug lots will be available on the market in 2019. In general, we are focused on the long-term perspective and expansion of our cooperation in the transition to a completely new innovative level of medical care for patients with chronic infectious diseases. This will significantly reduce the incidence rate, improve the life quality and life expectancy of patients. We are confident that as a result of the implementation of our project, we will be able to fully meet the need for antiretroviral and antiviral drugs in Russia.”